Top Buy Stocks
Sign In
Invest in AGIO
$29.59
-0.520 (-1.73%)
At Close: May 22, 2025
Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress
10:00am, Wednesday, 14'th May 2025
CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare disease
Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025
07:00am, Friday, 09'th May 2025
CAMBRIDGE, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced
Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates
08:55am, Friday, 02'nd May 2025
AGIO's earnings beat estimates in the first quarter of 2025, while revenues miss the same.
Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025
07:00am, Friday, 02'nd May 2025
CAMBRIDGE, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced
Agios Pharmaceuticals, Inc. (AGIO) Q1 2025 Earnings Call Transcript
12:06pm, Thursday, 01'st May 2025
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Chris Taylor – Vice President-Investor Relations and Corporate Communications
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates
08:50am, Thursday, 01'st May 2025
Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.55 per share versus the Zacks Consensus Estimate of a loss of $1.80. This compares to loss of $1.45 per share a year ago.
Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights
06:30am, Thursday, 01'st May 2025
– U.S. Regulatory Filing Under Active Review for Approval of PYRUKYND ® (mitapivat) in Thalassemia, with PDUFA Goal Date of September 7, 2025 – – Phase 3 RISE UP Study of Mitapivat in Sickle
Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for
11:05am, Thursday, 24'th Apr 2025
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025
07:00am, Thursday, 17'th Apr 2025
CAMBRIDGE, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare disea
New Strong Sell Stocks for April 8th
07:25am, Tuesday, 08'th Apr 2025
AFLYY, AGIO and ARLP have been added to the Zacks Rank #5 (Strong Sell) List on April 8, 2025.
New Strong Sell Stocks for April 3rd
04:55am, Thursday, 03'rd Apr 2025
AGIO, CHGG and EFX have been added to the Zacks Rank #5 (Strong Sell) List on April 3, 2025.
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer
05:52pm, Wednesday, 05'th Mar 2025
CAMBRIDGE, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare disea
Agios to Present at Upcoming Investor Conferences
07:00am, Tuesday, 04'th Mar 2025
CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announc
Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025
07:00am, Thursday, 20'th Feb 2025
CAMBRIDGE, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announce
Agios' Q4 Loss Wider Than Expected, Pyrukynd Drives Revenues
09:26am, Friday, 14'th Feb 2025
AGIO reports mixed fourth-quarter 2024 results. Its sole marketed drug, Pyrukynd, drives revenues year over year.
